+41 32 513 6767 | This email address is being protected from spambots. You need JavaScript enabled to view it.

Hansjörg Riedwyl as guest lecturer at the University of St. Gallen

54
On Wednesday, 16 October 2019 (16.15 - 18.00) Hansjörg Riedwyl, CEO of ISS AG in Biel, will give a guest lecture at the University of St. Gallen , Dufourstrasse 50 (room 09-011). The topic will be "Apps and other Software as Medical Device". Digital health interventions offer many new opportunities to all involved, but there are also hurdles to consider. This means that digital health...
Read More...

ISS-AG is co-author of the strategy paper " The future of previous OEM PLM constellations in the Medical Technology Industry", published by MedicalMountains GmbH.

98
With the application of the EU-MDR, the OEM/PLM relationships that have been frequently practiced so far will be a thing of the past. So far, the OEM ("Original Equipment Manufacturer") has been able to concentrate on the development and manufacture of its products and sell them without a name to a PLM ("Private Label Manufacturer") who was the sales expert. All he had to do was apply his own...
Read More...

Hansjörg Riedwyl Speaker at the MDR Support Panel - Third State Regulation

384
On October 23rd, 2019 the MDR Support Panel will take place in the new sitem-insel building, Freiburgstrasse 3, 3010 Bern. The background to this event is the adoption of the new EU legislation in the field of medical devices (MDR), for which regulatory issues in particular have not yet been clarified. The topic will be the regulation of third countries. As adoption of the framework agreement is...
Read More...

Hansjörg Riedwyl speaker at Medtech 2020 and Beyond: Tips for Survival in Europe’s New Medtech Environment Wednesday, October 30, Hotel Bellevue Palace, Bern

352
Hansjörg Riedwyl, CEO of ISS AG, Integrated Scientific Services, will have the opportunity to speak at the Event “Medtech 2020 and Beyond: Tips for Survival in Europe’s New Medtech Environment”, which will take place Wednesday, October 30 at the Hotel Bellevue Palace in Bern. The event addresses management and business development and focusses on strategic impact of the new EU Medical Devices...
Read More...

Successful OEM/PLM Symposium in Tuttlingen

465
Many business models in the Tuttlingen region are based on OEM/PLM constellations. Here the MDR (EU 2017/745) is a special challenge. At a symposium, the various aspects and possibilities were discussed and supplemented with concrete examples from practice. In a keynote speech, Hansjörg Riedwyl presented five different strategic options and made assessments on feasibility and the risks involved.
Read More...

Successful start of PEDeDose

335
The „Software as Medical Device“ (short: SaMD) product PEDeDose of the company PEDeus launched successfully in March 2019. PEDeDose supports healthcare professionals in prescribing pediatric medication and provides patient-specific information. The software can be accessed by any mobile- and desktop browser, or be transparently integrated into an existing system by using its web service. To...
Read More...

Manual and Checklists for the development of secure health apps

1789
ISS AG developed on behalf of eHealth Suisse a manual and checklists for the development of secure health apps. Software engineers have to ask themselves very early in the process of developing a health app, if their product falls into the category of a medical device and which regulation they have to adhere with. The manual supports the software engineers in this process. It provides practical...
Read More...

ISS Spin-off received IIb certification

1849
ISS spin-off, Optimo Medical AG , has received the certification for their class IIb product Optimeyes. This clears the way to use Optimeyes for very challenging operation planning in ophthalmology. To the best of our knowledge, Optimeyes is one of the first stand-alone software medical devices in Switzerland to overcome the considerable obstacle of the certification as a medical device in class...
Read More...

Event: New MedTech EU MDR/ IVDR Regulations - Consequences and Solutions (January 30th 2018)

8146
The new Medtech EU MDR/IVD regulations published at the end of May pose a major strategic and operative challenge to the entire industry, and they will have a major impact on the business performance of many companies and SMEs. All companies are strongly challenged. The first stakeholders have prepared GAP analyses to realize the tight implementation requirements by 2020 (MDR) and 2023 (IVDR)....
Read More...

ISS-Talk at the Tuttlinger Innovationsforum on October 19th

23212
Digital Regulatories is a hot topic. The title of Hanjoerg's (CEO of ISS AG) speech at the Tuttlinger Innovationsforum will be “Digital RA, a contribution to a shorter time to market”. The fact, that we were invited for this talk shows, that there is a lot of interest for this topic. However: ISS is investing for the simplification of Regulatory Submission processes by the means of IT for a long...
Read More...

3D Printing, impact of MDR

29988
ISS CEO Hansjörg Riedwyl is a speaker at the symposium “3D Printing for Life Sciences” in Muttenz on July 4th 2017. 3D Printing is one of the mega trends in Life Science. The Regulatory Situation is not clear in many aspects, therefor the potential impact of the new European regulation is of great interest. Hansjörg Riedwyl will point out, what is already clear, what the MDR will bring and where...
Read More...

Formation – Évaluation clinique selon MEDDEV 2.7/1, Révision 4

58902
ARIAQ et ISS AG proposent une formation d’une demi-journée pour les fabricants de dispositifs médicaux dont l’objectif est d’illustrer les exigences des évaluations cliniques selon « MEDDEV 2.7/1, Révision 4 » par des exemples concrets de mise en application en Suisse. Actuellement, la création d’une évaluation clinique est un défi pour l’industrie. Cette formation offre un programme ad hoc vous...
Read More...

Further clinical evaluation of ISS AG meets the requirements

50585
The process established by ISS AG for the preparation of clinical evaluations was again recognized by a positive assessment from a well-known Notified Body. "The clinical evaluation was established after MEDDEV 2.7.1 rev.4 and fulfills the requirements of MEDDEV 2.7.1 rev.4" We are very pleased that we have been able to support our customers in the certification of a Class IIb implant.
Read More...

ISS AG is now a member of the BVMA e.V.

53999
ISS AG has been accepted as a member of the BVMA e.V. The Federal Association of Contract Research Organisations (BVMA) e.V. was founded in July 1991 to represent CROs (Contract Research Organisations) which are based in Germany or German speaking countries.To make sure that each member satisfies the high quality demands, all members undergo re-auditing every three years. We are very pleased...
Read More...

ISS AG has been successfully audited as clinical Contract Research Organisation (CRO)

42617
The audit served to assess ISS’ adequacy and quality level in order to assure that the systems, procedures, practices and documentation at the CRO comply with Good Clinical Practice (ICH GCP), relevant national and international GCP requirements, CRO policies and procedures, and generally accepted good practices.
Read More...

Regulatory Affairs Software – No more missed deadlines

40797
Read our article in the medical journal DeviceMed With our Regulatory Affairs Software REGULA™ daily RA activities can be greatly simplified. This increases efficiency and shortens the time to market, which finally results in more turnover. This article was one of the most read DeviceMed articles in November 2016. Read our article in the medical journal DeviceMed to get more information about...
Read More...

Successful application of MEDDEV 2.7/1 Rev. 4 for clinical evaluations

29447
For several weeks now new, substantially stricter rules have been in place for clinical evaluations. All notified bodies known to us now require the application of Rev. 4 of the corresponding MEDDEV 2.7/1. The absence of an updated clinical evaluation according to Rev. 4 during an audit is considered to be a major non-conformity. We have adapted our processes and practice accordingly and in the...
Read More...

Successful maintenance audit for ISO 13485

41126
The ISO 13485 certification of the ISS AG was successfully maintained. The auditor issued a thoroughly good report and recommends maintaining the ISO 13485 certification without corrective actions requirements. This allows ISS to consolidate its position as a credible service provider in the fields of software development, regulatory affairs, clinical evaluations, clinical studies (CRO) and...
Read More...

Meet the Expert Implants Interlaken

53125
The abstract of SpineWelding and ISS AG is published. Our company, ISS AG, participated in the congress and was presenting together with SpineWelding AG an abstract on Clinical investigations with implants: View of the development company and of the CRO. Link eCM Journal
Read More...

Surveillance Audit by Notified Body DQS

54305
The QMS of ISS was recertified successfully by our Notified Body DQS. The main Focus of the audit was on the process of software development and the Clinical Research Organisation (CRO). The successful outcome is confirming our undertakings of the last months in further developing the CRO business. The audit was closed with no deviations noted.
Read More...

«i-net Medtech After-Work Regulatory Affairs Circle» with ISS AG

52464
The «i-net Med­tech Af­ter-Work Re­gu­la­to­ry Af­fairs Cir­cle» is based on re­quests from par­ti­ci­pants of last year’s i-net RA Stra­te­gy work­shop. The in­ten­ti­on of the cir­cle is to meet up twice a year to dis­cuss given RA cases and re­la­ted ac­tua­li­ties in an open and con­struc­tive man­ner. The cir­cle is de­di­ca­ted to med­tech re­la­ted RA, we ad­dress the event to peop­le and...
Read More...

Another success for REGULA™

49053
A multinational MedTec enterprise is using our RA software: After an intense evaluation phase, another multinational MedTec enterprise has decided to use REGULA™ for all its future submissions. In the already terminated first phase, RA processes of different locations were analysed and standards were searched and defined. The customer is seeking to harmonize and speed up RA processes globally,...
Read More...

Reinforcement of the ISS Team

41653
The ISS Team has received reinforcement: Dr. Michel Weber ISS AG decided to strengthen its competence in clinical operation services by building a separate organizational unit lead by Dr. Michel Weber joining the company. His experience as a former COO of international and Swiss Clinical Research and as Head of Clinical Research Operation at Novartis adds a lot of knowledge in all services...
Read More...

Talk at the ESCRS in Amsterdam with Harald Studer

267028
Harald Studer will have a lecture to a new study at the ESCRS in Amsterdam this year from 05-09 October 2013. The study was done in collaboration with the Ohio State University and compares the biomechanical effects of LASIK Flap and ReLEx Smile Cap Incisions.
Read More...